Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367651 | 0.85 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL5371594 | 0.84 | CALCRL (0.50) | CALCRLRAMP1CHRM4 | |
| SCHEMBL5365820 | 0.83 | CALCRL (0.57) | CALCRLRAMP1CHRM4PREP | |
| SCHEMBL5370418 | 0.80 | CALCRL (0.52) | CALCRLRAMP1CHRM4 | |
| SCHEMBL13907682 | 0.80 | OXTR (0.46) | CALCRLP2RY12RAMP1 | |
| SCHEMBL13907847 | 0.80 | CALCRL (0.47) | CALCRLRAMP1 | |
| SCHEMBL13907849 | 0.79 | SMYD3 (0.48) | CALCRLRAMP1 | |
| SCHEMBL14044283 | 0.78 | CALCRL (0.62) | CALCRLRAMP1CHRM4 | |
| SCHEMBL13907684 | 0.78 | CALCRL (0.46) | CALCRLRAMP1 | |
| SCHEMBL13907687 | 0.78 | POLB (0.47) | CALCRLPOLBRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | CALCRL 4/4885P2RY12 415/4885KMT2A 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.